BIIB Biogen Inc. stock chart & analysis
Conviction 32HealthcareScan · Fri, Nov 6, 2026Biogen Inc. (BIIB) closed at $248.35 (+1.81%) on Nov 6, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 57, RS Rating 95, -4.0% from its 52-week high, +41.2% year to date. Sector: Healthcare · Biological Products, (No Diagnostic Substances).
Financials as of Wed, Sep 30, 2026 · quarterly.
BIIB technical analysis
Trend
BIIB is in an uptrend: price is above the 50-day, which is above the 200-day moving average. It closed 8.0% above the 50-day ($230.01) and 22.3% above the 200-day ($203.18). ADX(14) at 30 points to a strong, established trend. It meets 8 of 8 trend-template criteria.
Momentum
RSI(14) is 57, in the bullish half of its range. MACD crossed below its signal line one session ago. Its RS Rating of 95 puts its weighted 12-month performance ahead of about 95% of the US market, and its RS line is at a new high.
Volume and volatility
Volume on the latest session ran 0.7× its 20-day average. It trades about $331.1M a day on average. ATR(14) is $8.14, 3.3% of price — its typical daily range. On-balance volume is trending up. Chaikin Money Flow (-0.09) shows distribution.
Key levels
The chart pattern's support is $215.16 and its resistance $256.60. The 52-week range is $151.83 to $258.78; price is 4.0% below the high and 63.7% above the low. The VWAP anchored at the 52-week high is $250.03, above price.
Performance
BIIB returned -2.0% (1 week), +13.8% (1 month), +20.0% (3 months), +28.5% (6 months), +62.0% (1 year), +41.2% (year to date).
About Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Biological Products, (No Diagnostic Substances) · Listed 1991 · 7,500 employees
Signal lifecycle
How this symbol has moved through the lanes across 60 scans — each scan is re-classified from that day's price, so gaps are days it dropped off the board entirely.
- Setting upAug 181 scan
- Breaking out nowAug 191 scan
- Setting upAug 20 – Aug 243 scans
- Breaking out nowAug 251 scan
- Broke outAug 261 scan
- Setting upAug 27 – Sep 14 scans
- Breaking out nowSep 21 scan
- Broke outSep 31 scan
- Setting upSep 41 scan
Congress activity
Disclosed STOCK Act trades in BIIB · 10 recent
| Member | Side | Amount | Traded | Filed | PTR |
|---|---|---|---|---|---|
 Maria Elvira Salazar house · R · FL · traded 2026-09-24 | Sell | $1K–$15K | 2026-09-24 | 2026-10-07 | |
 Kevin Hern house · R · OK · traded 2026-08-18 | Sell | $1K–$15K | 2026-08-18 | 2026-09-01 | |
 Alan Armstrong senate · R · OK · traded 2026-03-27 | Buy | $1K–$15K | 2026-03-27 | 2026-07-21 | |
Maria Elvira Salazar house · R · FL · traded 2026-06-02 | Sell | $15K–$50K | 2026-06-02 | 2026-07-07 | |
 Gilbert Cisneros house · D · CA · traded 2026-06-05 | Buy | $1K–$15K | 2026-06-05 | 2026-07-02 | |
Maria Elvira Salazar house · FL · traded 2026-05-11 | Buy | $1K–$15K | 2026-05-11 | 2026-06-01 | |
Maria Elvira Salazar house · FL · traded 2026-05-12 | Buy | $1K–$15K | 2026-05-12 | 2026-06-01 | |
Maria Elvira Salazar house · FL · traded 2026-05-11 | Buy | ≥ $50K | 2026-05-11 | 2026-06-01 | |
Gilbert Cisneros house · CA · traded 2026-01-30 | Buy | $1K–$15K | 2026-01-30 | 2026-02-11 | |
 Rob Bresnahan house · PA · traded 2025-05-15 | Buy | $1K–$15K | 2025-05-15 | 2025-06-09 |
Insider activity
SEC Form 4 transactions in BIIB · open-market 2 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Grogan Jane Head of Research · Common Stock · 2026-10-30 | Tax | 345 | $87K | 2026-10-30 | 2026-11-02 |
Grogan Jane Head of Research · Restricted Stock Unit · 2026-10-30 | Exercise | 695 | — | 2026-10-30 | 2026-11-02 |
Grogan Jane Head of Research · Common Stock · 2026-10-30 | Exercise | 695 | — | 2026-10-30 | 2026-11-02 |
Godbout Sean Chief Accounting Officer · Restricted Stock Unit · 2026-10-02 | Exercise | 27 | — | 2026-10-02 | 2026-10-05 |
Godbout Sean Chief Accounting Officer · Common Stock · 2026-10-02 | Exercise | 27 | — | 2026-10-02 | 2026-10-05 |
Godbout Sean Chief Accounting Officer · Common Stock · 2026-10-02 | Tax | 8 | $2K | 2026-10-02 | 2026-10-05 |
Godbout Sean Chief Accounting Officer · Restricted Stock Unit · 2026-10-01 | Grant | 985 | — | 2026-10-01 | 2026-10-05 |
Minor Lloyd Director · Common Stock · 2026-08-04 | Sell | 593 | $119K | 2026-08-04 | 2026-08-05 |
Minor Lloyd Director · Common Stock · 2026-08-03 | Sell | 593 | $121K | 2026-08-03 | 2026-08-05 |
Keeney Adam Head of Corporate Development · Common Stock · 2026-05-01 | Tax | 455 | $85K | 2026-05-01 | 2026-05-05 |
SEC filings
EDGAR filings in BIIB · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.